Table 3.

Adequate clinical and Parasitological response (ACPR) in the intention-to-treat population

	Pyronaridine–artesunate (n = 101)	Artemether–lumefantrine (n = 96)	Difference (95% CI)
Day 28
PCR-corrected ACPR, n/Na	93/101	81/96
% (95% CI)	92.1 (85.1 to 95.9)	84.4 (75.8 to 90.3)	7.7 (− 1.4 to 17.1)
Total no. of failures	8 (7.9)	15 (15.6)
No. with missing data	6 (5.9)	11 (11.5)
No. with early treatment failure	0	0
No. with late clinical failure	0	0
No. with late parasitological failure	1 (1.0)	3b (3.1)
No. with reinfection < day 28	1 (1.0)	1 (1.0)
Uncorrected ACPR, n/N	87/101	75/96
% (95% CI)	86.1 (78.1 to 91.6)	78.1 (68.9 to 85.2)	8.0 (− 2.7 to 18.8)
Total no. of failures	14 (13.9)	21 (21.9)
No. with missing data	6 (5.9)	11 (11.5)
No. with early treatment failure	0	0
No. with late clinical failure	1 (1.0)	1 (1.0)
No. with late parasitological failure	7 (6.9)	9 (9.4)
Day 42
PCR-corrected ACPR, n/Na	73/101	61/96
% (95% CI)	72.3 (62.9 to 80.1)	63.5 (53.6 to 72.5)	8.7 (− 4.3 to 21.4)
Total no. of failures	28 (27.7)	35 (36.5)
No. with missing data	15 (14.9)	19 (19.8)
No. with early treatment failure	0	0
No. with late clinical failure	1 (1.0)	0
No. with late parasitological failure	3b (3.0)	6c (6.3)
No. with reinfection < day 42	9 (8.9)	10 (10.4)
Uncorrected ACPR, n/N	67/101	56/96
% (95% CI)	66.3 (56.7 to 74.8)	58.3 (48.3 to 67.7)	8.0 (− 5.5 to 21.1)
Total no. of failures	34 (33.7)	40 (41.7)
No. with missing data	15 (14.9)	19 (19.8)
No. with early treatment failure	0	0
No. with late clinical failure	5 (5.0)	2 (2.1)
No. with late parasitological failure	14 (13.9)	19 (19.8)

Data are n (%) unless otherwise indicated

^aPCR-corrected for reinfection by msp1, msp2 and glurp genotyping

^bOne of the late parasitological failures had indeterminate genotyping and was marked as recrudescence

^cTwo of the late parasitological failures had indeterminate genotyping and were marked as recrudescence